Mesoblast set for Asian launch
Monday, 16 February, 2009
Melbourne biotech Mesoblast has signed a collaborative program with Singapore’s Parkway Group Healthcare to trial its cartilage stem cell product RepliCart.
RepliCart is aimed at preventing or treating osteoarthritis of the knee, both in the elderly and following knee reconstruction surgery.
Last month, Mesoblast announced it was beginning Phase II trials of RepliCart in people under 40 who had undergone anterior cruciate ligament surgery
The agreement with Parkway Group Healthcare, which operates 15 private hospitals in Asia, involves a single-injection safety and efficacy trial at Parkway’s Clinical Centre of Excellence in Singapore.
Mesoblast said further trials were planned for additional clinical indications.
SEQ koala population carries immunity to retrovirus
Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...
RSV immunisation program for babies slashes hospital stays
An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...
A targeted treatment option for psoriasis
New research from MedUni Vienna paves the way for the development of a therapy that not only...
